78 related articles for article (PubMed ID: 29110262)
1. Mutational Diversity of Lung Cancer and Associated Lymph Nodes. An Exploratory Prospective Study of 4 Resected cIIIA-N2.
Legras A; Roussel H; Mangiameli G; Arame A; Grand B; Pricopi C; Badia A; Gibault L; Badoual C; Fabre E; Laurent-Puig P; Blons H; Le Pimpec-Barthes F
Pathol Oncol Res; 2019 Jan; 25(1):319-325. PubMed ID: 29110262
[TBL] [Abstract][Full Text] [Related]
2. Genomic landscape of metastatic lung adenocarcinomas from large-scale clinical sequencing.
Li D; Huang Y; Cai L; Wu M; Bao H; Xu Y; Wei Y; Wu S; Wu X; Shao Y; Zhao W; Lv G; Huang S; Zhang T; Shi Y
Neoplasia; 2021 Dec; 23(12):1204-1212. PubMed ID: 34735995
[TBL] [Abstract][Full Text] [Related]
3. Stepwise addition of genetic changes correlated with histological change from "well-differentiated" to "sarcomatoid" phenotypes: a case report.
Goto T; Hirotsu Y; Mochizuki H; Nakagomi T; Oyama T; Amemiya K; Omata M
BMC Cancer; 2017 Jan; 17(1):65. PubMed ID: 28103823
[TBL] [Abstract][Full Text] [Related]
4. An integrated inspection of the somatic mutations in a lung squamous cell carcinoma using next-generation sequencing.
Stead LF; Egan P; Devery A; Conway C; Daly C; Berri S; Wood H; Belvedere O; Papagiannopoulos K; Ryan A; Rabbitts P
PLoS One; 2013; 8(11):e78823. PubMed ID: 24244370
[TBL] [Abstract][Full Text] [Related]
5. Paired analysis of tumor mutation burden for lung adenocarcinoma and associated idiopathic pulmonary fibrosis.
Yoneshima Y; Iwama E; Matsumoto S; Matsubara T; Tagawa T; Ota K; Tanaka K; Takenoyama M; Okamoto T; Goto K; Mori M; Okamoto I
Sci Rep; 2021 Jun; 11(1):12732. PubMed ID: 34140559
[TBL] [Abstract][Full Text] [Related]
6. The genomic dynamics during progression of lung adenocarcinomas.
Yang B; Luo L; Luo W; Zhou Y; Yang C; Xiong T; Li X; Meng X; Li L; Zhang X; Wang Z; Wang Z
J Hum Genet; 2017 Aug; 62(8):783-788. PubMed ID: 28381877
[TBL] [Abstract][Full Text] [Related]
7. Differences in mutational processes and intra-tumour heterogeneity between organs: The local selective filter hypothesis.
Giraudeau M; Sepp T; Ujvari B; Renaud F; Tasiemski A; Roche B; Capp JP; Thomas F
Evol Med Public Health; 2019; 2019(1):139-146. PubMed ID: 31528343
[TBL] [Abstract][Full Text] [Related]
8. Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
Tanizaki J; Haratani K; Hayashi H; Chiba Y; Nakamura Y; Yonesaka K; Kudo K; Kaneda H; Hasegawa Y; Tanaka K; Takeda M; Ito A; Nakagawa K
J Thorac Oncol; 2018 Jan; 13(1):97-105. PubMed ID: 29170120
[TBL] [Abstract][Full Text] [Related]
9. Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas.
Lococo F; Torricelli F; Rossi G; Alifano M; Damotte D; Rapicetta C; Tamagnini I; Cavazza A; Piana S; Galeone C; Paci M; Ciarrocchi A
Lung Cancer; 2017 Nov; 113():93-101. PubMed ID: 29110857
[TBL] [Abstract][Full Text] [Related]
10. Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy.
Hochmair MJ; Schwab S; Burghuber OC; Krenbek D; Prosch H
Lung Cancer; 2017 Nov; 113():4-6. PubMed ID: 29110847
[TBL] [Abstract][Full Text] [Related]
11. Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1.
Iwata T; Yamamoto A; Hara K
J Thorac Oncol; 2017 Dec; 12(12):e205-e207. PubMed ID: 29169526
[No Abstract] [Full Text] [Related]
12. Can radiotherapy potentiate the effectiveness of immune checkpoint inhibitors in lung cancer?
Cheng M; Durm G; Hanna N; Einhorn LH; Kong FS
Future Oncol; 2017 Dec; 13(28):2503-2505. PubMed ID: 29168656
[No Abstract] [Full Text] [Related]
13. [Advances of the Role of Lung Cancer Driver Gene and PD-1/PD-L1 Pathway Interaction in the Tumorigenesis and Progression of Non-small Cell Lung Cancer].
Shi Y; Lv W; Wang L; Hu J
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):781-786. PubMed ID: 29167009
[TBL] [Abstract][Full Text] [Related]
14. Will liquid biopsies become our fluid transition to personalized immunotherapy?
Wauters E; Vansteenkiste J
Ann Oncol; 2018 Jan; 29(1):11-13. PubMed ID: 29165546
[No Abstract] [Full Text] [Related]
15. Nivolumab in non-small-cell lung cancer with EGFR mutation.
Yoshida H; Kim YH; Ozasa H; Nagai H; Sakamori Y; Tsuji T; Nomizo T; Yasuda Y; Funazo T; Hirai T
Ann Oncol; 2018 Mar; 29(3):777-778. PubMed ID: 29161357
[No Abstract] [Full Text] [Related]
16. Correlation of cancer stem cell markers and immune cell markers in resected non-small cell lung cancer.
Huang Z; Yu H; Zhang J; Jing H; Zhu W; Li X; Kong L; Xing L; Yu J; Meng X
J Cancer; 2017; 8(16):3190-3197. PubMed ID: 29158791
[No Abstract] [Full Text] [Related]
17. Immunotherapy: Gut bacteria modulate responses to PD-1 blockade.
Killock D
Nat Rev Clin Oncol; 2018 Jan; 15(1):6-7. PubMed ID: 29158588
[No Abstract] [Full Text] [Related]
18. Impressive response to immunotherapy in a metastatic gastric cancer patient: could somatic copy number alterations help patient selection?
Dos Santos Fernandes G; da Motta Girardi D; Dib Batista Bugiato Faria L; Giacomini Bernardes JP; de Almeida Coudry R
J Immunother Cancer; 2017 Nov; 5(1):84. PubMed ID: 29157298
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers for immunotherapy in bladder cancer: a moving target.
Aggen DH; Drake CG
J Immunother Cancer; 2017 Nov; 5(1):94. PubMed ID: 29157296
[TBL] [Abstract][Full Text] [Related]
20. PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.
Peters S; Kerr KM; Stahel R
Cancer Treat Rev; 2018 Jan; 62():39-49. PubMed ID: 29156447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
